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ess under CC BY-NC-Abstract Acitretin is a photosensitive oral retinoid with very limited data available on its degradation. The
ofﬁcial HPLC method for acitretin determination was insufﬁcient to resolve the degradation products generated
during stability studies. Therefore, an isocratic RP-HPLC–UV method was developed for the determination of
acitretin in the presence of its related impurities and degradation products. Efﬁcient chromatographic separation
was achieved on a Thermo beta-basic column C18 (100 mm 4.6 mm, 5 μm) with mobile phase containing
0.3% (v/v) glacial acetic acid with acetonitrile (ACN) and isopropyl alcohol (IPA) in an isocratic ratio of 70:30 at
a ﬂow rate of 1.0 mL/min with the eluent monitored at 360 nm. The method was validated for speciﬁcity,
linearity, precision, accuracy and robustness. The calibration plot was linear over the concentration range of 50–
150 μg/mL with a correlation coefﬁcient (r2) of 0.999. The proposed method was used to investigate the
degradation kinetics of acitretin under the different degradative conditions. The degradation rate constant (K),
half-life (t1/2), and t90 were calculated. Degradation of acitretin followed pseudo-ﬁrst-order kinetics. The drug was
found to be less stable under acidic and photolytic degradation conditions: the photolytic degradation constants
for acitretin in sunlight and UV light were 0.002698% and 0.0008402% min1, respectively. The LOD for
acitretin and the known impurities were at a level below 0.02%. The method shows consistent recoveries for
ACTR (99.8%–101.2%) and also for its known impurities (97.2–101.3%). The method was found to be accurate,
precise, linear, speciﬁc, sensitive, rugged, robust, and useful for characterizing the stability of this chemical.
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Acitretin (ACTR; (all-E)-9-(4-methoxy-2,3,6-trimethylphenyl)-
3,7-dimethylnona-2,4,6,8-tetraenoic acid, Fig. 1), an oral retinoid,
is used as a ﬁrst line treatment for psoriasis1. Acitretin works by
inhibiting the excessive cell growth and keratinization seen in
psoriasis. It therefore reduces the thickening of the skin, plaque
formation and scaling2.
Regulatory requirements for the identiﬁcation, quantiﬁcation, and
control of impurities in drug substances and their formulated
products are now being explicitly deﬁned, particularly through the
International Conference on Harmonization (ICH). It is also
recommended by ICH that all routine impurities at or above 0.1%
level should be identiﬁed through appropriate analytical methods3–5.
ACTR is cited in the European Pharmacopoeia to contain the imp-A
((2Z,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-
nona-2,4,6,8-tetraenoic acid, Fig. 1) and imp-B (ethyl (all-E)-9-(4-
methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraeno-
ate, Fig. 1)6. Therefore, it was thought worth determining the
impurities of ACTR to ensure the quality, efﬁcacy and safety of
the ﬁnal pharmaceutical formulation. To this end, a method for
analyzing ACTR in the presence of its two known impurities
(imp-A and imp-B) was developed. Tretinoin, all trans-retinoic acid
((all-E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-
nonatetraenoic acid, Fig. 1), is likely to be present in formulations of
acitretin6. Therefore, in addition to the known impurities of ACTR,
tretinoin was also analyzed in this study.
A literature survey revealed that few publications are reported
for estimation of ACTR in pharmaceutical preparations as well as
in biological ﬂuids. Surber and Laugier et al.7 have reported an
HPLC method for the determination of ACTR in human plasma
and further applied it to a pharmacokinetic study. Liquid chroma-
tography with tandem mass spectrometry methods has been used
for quantitation of ACTR in human plasma either alone8, in
combination with its metabolite9 or in combination with other
drugs10. A spectroﬂuorimetric method has been reported for the
determination of acitretin in pharmaceuticals in the concentration
range of 30.0–1100 ng/mL11. The ofﬁcial HPLC method6 for
ACTR analysis includes a C18 stationary phase with 0.3% (v/v)
solution of glacial acetic acid (GAA) in a mixture of water and
ethanol in the ratio of 8:92 (v/v) as mobile phase at reduced ﬂow
rate (i.e., 0.6 mL/min). The method results in a long run time to
elute ACTR and its known impurities, and did not provide stability
information essential for regulatory submission. The run time
could be shortened by increasing the ﬂow rate.CH3
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Figure 1 Chemical structures of acetFrom the preceding details it is apparent that a validated method
is required to be developed which would provide simultaneous
determination of ACTR in the presence of its reported impurities,
and also provide an indication of ACTR stability. Thus, the aim of
current study was to develop and validate a LC method for the
determination of ACTR and its known impurities (imp-A, imp-B
and tretinoin) along with its degradation products when provided
in a capsule dosage form, in accordance with the ICH guidance
document12.2. Materials and methods
2.1. Reagents and chemicals
Qualiﬁed standards of ACTR and its related imp-A imp-B were a
gift from Torrent Research Centre (Ahmadabad, India). Analytical/
HPLC grade chemicals and solvents were obtained from Ranbaxy
Fine Chemicals Limited (Delhi, India).
2.2. Chromatography apparatus and conditions
The chromatograph consisted of a HP-Agilant 1100 HPLC System
with G1311A Quaternary Pump, G1315A Diode Array Detector
and variable wavelength detector, a G1313A Autosampler, and a
G1322A Vacuum Degasser. The data were evaluated by HP
Chemstation Software.
Optimum separation conditions were obtained with a Thermo
Beta basic C18 (100 mm 4.6 mm, i.d. 5.0 μm, 150 Å pore size)
column with mobile phase consisting of ACN:IPA:GAA in the
ratio of 70:29.7:0.3 (v/v/v) with column oven temperature main-
tained at 25 1C and elution monitored by a UV detector at 360 nm.
All measurements were performed with an injection volume of
20 μL of sample dissolved in a diluent:acetonitrile and isopropyl
alcohol in ratio of 80:20.
2.3. Preparation of solutions
2.3.1. Preparation of resolution solution
As enumerated in the ofﬁcial procedures for analysis of ACTR6,
tretintoin, imp-A and imp-B were dissolved in 60 mL of diluent in
a 100 mL volumetric ﬂask. The standard solution was sonicated at
1072 1C for 10 min. The volume of the clear solution obtained
was made up to 100 mL with the diluent to give the resolutionCH3
3CO
CH3
CH3
CH3 CH3
CO2H
CH3
CH3 CH3 CH3 O
OH
CH3
CH3
Tretinoin
Imp-A
retin, imp-A, imp-B and tretinoin.
Pawan K. Porwal, Neeraj Upmanyu440solution containing 100 μg/mL ACTR, and 10 μg/mL each of imp-
A and imp-B.2.3.2. Preparation of laboratory mixture solutions
Appropriate amounts of ACTR, tretinoin, imp-A, imp-B and
excipients equivalent to the average weight of the capsule powder
were transferred to a 100 mL volumetric ﬂask. About 60 mL of
diluent was added and sonicated for 10 min at 10 1C with
intermittent shaking and diluted to volume with the diluent to
contain 100 μg/mL ACTR and 1.0 μg/mL each of known impurity.
This solution was ﬁltered through a 0.45 μm Nylon 66-membrane
ﬁlter and used for the analysis.2.3.3. Preparation of sample solution
The average weight of 20 capsules was determined. The ﬁll of 20
capsules was removed and an amount equivalent to 10 mg of the
active pharmaceutical ingredient (ACTR) was transferred to a
100 mL volumetric ﬂask. Diluent (60 mL) was added and the ﬂask
solution was sonicated for 10 min at 10 1C with intermittent
shaking and diluted to volume with the diluent. This solution
was ﬁltered through a 0.45 μm Nylon 66-membrane ﬁlter and used
for the analysis. A similar method was employed to prepare the
placebo solution.2.4. System suitability
System suitability parameters were evaluated to verify that the
analytical system was working properly and would give accurate
and precise results. Parameters such as peak asymmetry factor,
tailing factor, resolution between imp-A and ACTR and RSD (%)
of theoretical area obtained from two resolution solutions (in
triplicate) were evaluated.2.5. Filter-compatibility studies
A laboratory mixture solution was subjected to ﬁlter-compatibility
studies. The solution was ﬁltered using Whatmans ﬁlter paper No.
42 and 0.45 μm Nylon 66-membrane ﬁlter. Another laboratory
mixture solution was centrifuged (unﬁltered). Chromatography
was performed on these three solutions, in triplicate, and differ-
ence between concentrations of each component in ﬁltered and
unﬁltered sample solutions was calculated.2.6. Analytical method validation
2.6.1. Speciﬁcity
Speciﬁcity is the ability of the method to measure the analyte
response in the presence of its potential impurities and degradation
products. The speciﬁcity studies were carried out in two parts
namely part-A and part-B. In speciﬁcity part-A, separation and
resolution were observed between diluent, known impurities,
degradation product(s), placebo solution, and ACTR standard
solution.
Whereas, in speciﬁcity forced degradation studies for acitretin
were designed and executed as per guidelines described in the
literature13. The forced degradation rate constant was calculated using
Graphpad Prisms Version 5.01 software. To prevent any possible
photodegradation all experiments were performed in dimmed light.2.6.2. Linearity
Linearity test for the method was performed according to the
guidelines described by ICH. Appropriate aliquots of ACTR
stock solution were diluted with the diluent to appropriate
concentrations and the linearity of ACTR was determined; the
range was inclusive of concentrations at 50%, 80%, 100%, 120%
and 150% of test concentration.
A calibration curve was drawn by plotting the peak areas of
ACTR versus its corresponding concentration. The process was
repeated for three consecutive days in the same concentration
range. Values of coefﬁcient of regression, slope and Y-intercept of
the calibration curve were calculated.
2.6.3. Precision
Six solutions containing ACTR (100 μg/mL) were prepared sepa-
rately. Chromatography was performed and the value of RSD (%)
was calculated considering peak area for ACTR. Similarly, inter-
mediate precision of the method was also evaluated by another
analyst, on a different day in the same laboratory.
2.6.4. Limit of detection (LOD) and limit of quantiﬁcation
(LOQ)
The LOD and LOQ for ACTR and all related substance (RS) were
estimated by signal-to-noise ratio, 3:1 and 10:1, respectively,
injecting a series of six diluted solutions of ACTR and its RS in
known concentrations.
2.6.5. Accuracy
Recovery studies were performed in triplicate at concentration
levels of 50%, 100% and 150% of ACTR (100 μg/mL) to evaluate
the accuracy of the proposed method. Solutions for the purpose
were prepared by standard addition of ACTR stock solution to
laboratory mixture solution.
2.6.6. Stability of laboratory mixture solution
The stability of the ACTR stock solution (100 μg/mL) and the
laboratory mixture solution was evaluated at regular intervals for
24 h at room temperature and at 10 1C. The difference in areas of
the respective peaks in the chromatograms was calculated.
2.6.7. Robustness
The method was performed with small variations such as a
composition of the mobile phase (72% of IPA), a change to the
mobile phase ﬂow rate (70.2 mL/min), and increasing the
temperature from normal (75 1C). Chromatograms of six replicas
of the laboratory mixture solution were obtained and the effect of
each deliberate change was evaluated by applying system suit-
ability parameters and calculating value of RSD (%) for each
deliberate change.
2.7. Application of the validated method
2.7.1. Laboratory mixture
The validated method was applied to a known laboratory solution
of ACTR. A series of laboratory solutions containing 8.0, 10.0 and
12.0 μg/mL of ACTR were prepared and the concentration of the
analyte was back-calculated.
2.7.2. Assay of ACTR in marketed dosage form
A marketed formulation containing ACTR (10 mg of ACTR as the
active pharmaceutical ingredient) was diluted to a concentration of
Degradation behavior of acitretin 44110 μg/mL with diluent. Each of the solutions was prepared in
triplicate and chromatograms were recorded and the percent assay
was calculated.3. Results and discussion
3.1. Development of the chromatographic method
The ofﬁcial HPLC method6 to analyze ACTR and its RS could not
be used to determine drug stability, and using these methods to
analyze samples of ACTR capsules treated with acid, alkali,
hydrogen peroxide, heat and light and spiked with laboratory
mixture solution did not yield satisfactory results. The methods
were not able to produce sufﬁcient resolution between degradation
products with the RS. The chromatogram of sample containing
degradation products generated by photolytic stress showed
elution of acitretin related imp-A and degradation products at
relative retention time (RRT) 0.943 and RRT 1.06 which did not
meet the acceptance criteria for peak purity. Additionally, the
method applied to samples of alkaline degradation yielded a
chromatogram displaying co-elution of degradation products at
the same RRT. Moreover, the ofﬁcial HPLC method for assay of
ACTR yields a 460 min elution time for imp-B (Fig. 2a).
ACTR, pKa 4.7914, was slightly soluble in selected analytical
solvents like ACN, tetrahydrofuran (THF), IPA and methanol. ACTR
was practically insoluble in water. The chromatographic conditions
were optimized by different means (using different columns, different
buffers and different organic phases). The goal of the method under
development was envisaged to be capable of eluting wide range of
compounds of different polarities, with excellent efﬁciency and
sufﬁcient band spacing in a shorter run time. During development
of chromatographic method elution was performed using C18
columns having pore size of about 150 Å. Mobile phase consisting
ACN, IPA, 50 mmol/L potassium phosphate buffer and various
volumes of GAA in water was used preliminary in isocratic elution.
The chromatogram showed co-elution of imp-A with ACTR.
Increasing the proportion of ACN in the mobile phase resulted in
rapid elution of acitretin with co-elution of impurity. Replacement of
the potassium phosphate component with GAA yielded a mobile
phase ACN:IPA:GAA in the ratio of 80:19.7:0.3 (v/v/v) and at a ﬂowFigure 2 The chromatograms of ACTR and its RS in ofﬁcirate 1.0 mL/min gave optimum resolution in separate peaks of ACTR
and its RS, although tailing was observed in few peaks. However,
very late elution of tretinoin and imp-B was observed, making the
ofﬁcial HPLC method time-consuming. Therefore, the proportion of
IPA was increased from 20% to 30% of mobile phase. The ﬁnal
mobile phase was ACN:IPA:GAA in the ratio of 70:29.7:0.3 (v/v/v).
The mobile phase was mixed and eluted at 1.0 mL/min by the system
and the column temperature was maintained at 25 1C.
3.2. System suitability
Chromatographic separation was performed with a Thermo Beta
basic C18 (100 mm 4.6 mm, i.d. 5.0 μm) column with the
above-mentioned mobile phase and a representative chromatogram
is shown in Fig. 2b, which displays a tailing factor less than 1.5 for
all the peaks and a resolution of 10.3 for impurity-A with respect
to ACTR. The RSD (%) of the peak areas of six injections ACTR
standard solution was 1.6.
Tailing factor, a parameter that ICH guidelines consider as a
factor to be controlled, was within the established limits. The
resolution factor between two consecutive peaks represents
approximately twice the minimum request to be considered. The
results of system suitability studies are shown in Table 1.
3.3. Filter compatibility studies
The results of the ﬁlter compatibility studies for unﬁltered and
ﬁltered methods are tabulated in Table 2, and indicate that either a
0.45 μm ﬁlter or a Whatman ﬁlter can be used for regular analysis.
3.4. Speciﬁcity
The HPLC chromatograms recorded for ACTR alone and with its RS,
blank, and placebo preparations displayed a single, non-overlapped
peak for ACTR. The resolution factor obtained between the peak for
ACTR and other peaks was more than 2.1 and the tailing factor of the
peak for ACTR and the RS was always in the range 1.03–1.50.
Thus, the HPLC method presented in this study is selective for ACTR
and also for the other related compounds, which might co-exist as
impurities. The degradation kinetics of ACTR is shown in Fig. 3.al method (a) and under optimized HPLC conditions (b).
Table 1 System suitability studies for resolution solution of ACTR and its RS (n¼6) in the optimized ion pair-HPLC method.
System suitability parameter USP limit ACTR imp-A imp-B Tretintoin
Retention time – 13.61 8.36 37.55 20.77
RSD (%) of Rt – 0.56 0.30 0.15 0.64
RSD (%) of peak area r2.0 0.65 1.90 1.26 0.50
Peak asymmetry factor (at 10%) r1.5 1.15 1.01 1.08 1.21
Capacity factor (k0) 5–20 5.35 2.90 16.54 8.70
Table 2 Difference in percent peak area of ﬁltered sample solutions with unﬁltered sample.
Compound Difference with unﬁltered sample %
Set-1 Set-2
0.45 mm ﬁlter Whatman ﬁlter 0.45 mm ﬁlter Whatman ﬁlter
ACTR 1.5 1.7 0.4 3.7
Tretintoin 1.7 2.7 0.5 0.1
imp-A 1.8 4.2 1.0 0.2
imp-B 1.6 6.6 0.9 1.0
Total impurity 1.0 0.7 0.8 0.0
Figure 3 The degradation behavior of ACTR under different
conditions.
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suggested the degradation behavior tabulated in Table 3.
3.4.1. Degradation under acidic conditions
ACTR was observed to be degraded to about 40% under acidic
conditions, when treated with 1 mol/L HCl for 6 h at room
temperature. imp-A was obtained as the major degradation product
(12.52%) and eluted at 0.60 RRT as shown in Fig. 4a. ACTR was
found to be relatively stable (E95.0% remaining) under less
intense stress conditions (0.1 mol/L HCl for 6 h at room tempera-
ture) with imp-A as the only degradation product. The degradation
rate constant under acidic condition (1 mol/L HCl for 6 h at room
temperature in dark) was 1.26 106% min1 with degradation
half-life more than 6 days.
3.4.2. Degradation under basic conditions
ACTR was found to be degraded to 70.0% when treated with 1 mol/L
NaOH for 6 h at room temperature. The chromatogram (Fig. 4b)
displayed imp-A as a major degradation product (10.06%), eluting at
0.60 RRT. ACTR was found to be stable (E98.5% remaining) under
less alkaline conditions (0.1 mol/L NaOH for 1 h at 80 1C) with imp-
A as the only degradation product. Results of the degradation studies
suggest long term storage of the drug leads to degradation, with a fall
in the content of ACTR and a corresponding rise in imp-A.
3.4.3. Degradation under oxidative conditions
The drug was degraded to 80% in the presence of peroxide (3% H2O2
at 80 1C for 1 h) with imp-A as a major degradation product eluting at
0.62 RRT. The chromatogram (Fig. 4c) displayed more than 3
degradation products. ACTR was relatively stable (98.02% remaining)
under milder oxidative conditions (3% H2O2 at 80 1C for 10 min).
3.4.4. Degradation under photolytic conditions
ACTR was found to be highly unstable when exposed to 1.2 million
Lux hours with near-UV energy Z200 Wh/m2; the chromatogram isshown in Fig. 4d. The chromatogram displayed imp-A as major
degradation product (12.06%) showing elution at 0.61 RRT. The
degradation rate constant was 0.0008402% min1. Results of the
degradation studies suggest long term storage of the drug under
photolytic conditions leads to degradation, with a fall in the content of
ACTR and a corresponding rise in degradation products.
3.4.5. Thermal degradation
Unalterd drug content was reduced to about 90% upon dry heat
degradation (80 1C for 8 h) with an unknown degradation product
Table 3 Kinetics of ACTR degradation under different conditions.
Acidic
hydrolysis
Basic
hydrolysis
Neutral
hydrolysis
Sunlight
degradation
UV-Light
degradation
Thermal
degradation
Peroxide
degradation
One phase decay Unclear Unclear Unclear Exponential Exponential Exponential Unclear
ACTR remaining (%) 41.1 72.8 95.7 66.7 78.9 91.5 79.0
Peak purity of ACTR
peak
0.9997 0.9999 0.9999 0.9999 0.9998 0.9999 0.9996
Y 99.29 99.88 100.0 99.31 99.94 99.36 100.2
Plateau 41,260 44,000 24,110 36.10 14.43 46.08 96,750
K (% min1) 1.26 106 9.055 107 3.950 107 0.002698 0.0008402 0.0007584 8.794 107
Half-life (min) 547,079 765,481 1.755 106 256.9 825.0 913.9 788,212
R2 0.9809 0.9916 0.9631 0.9934 0.9933 0.9676 0.9925
Absolute sum of
squares
15.38 3.886 1.007 23.92 13.56 12.17 15.72
Sy.x 0.8997 0.4522 0.2302 1.122 0.8449 0.8004 0.9096
Figure 4 The chromatogram of the sample with acid-treated (a), alkali-treated (b), peroxide-treated (c), photolytically-treated (d), heat-treated (e),
and neutral-treated (f).
Degradation behavior of acitretin 443eluting at 0.86 RRT. The chromatogram (Fig. 4e) displayed two
degradation products.
3.4.6. Degradation under neutral conditions
ACTR was found to lose about 4.25% under neutral conditions
(reﬂuxed in water for 2 h at 80 1C) and two unknown degradation
products (at RRT 0.82 and 0.86) were formed under these
conditions; the chromatogram is shown in Fig. 4f.3.5. Linearity
Calibration curves for ACTR and its RS, examined in pure
solutions as well as in the Laboratory mixture solution, were
found to be linear; correlation coefﬁcients were Z0.997 in all
cases. Table 4 lists the linearity parameters of the calibration
curves for ACTR and RS in Laboratory mixture. UV-relative
Table 4 Range of linearity ACTR and its RS.
Compound Linearity range (mg/mL) R2 Slope Intercept Standard error t-Stat P FR
ACTR 0.35–1.50 0.999 34.62 0.80 0.39 2.05 0.06
Tretintoin 0.20–1.50 0.998 32.76 0.33 0.323 1.01 0.33 0.95
imp-A 0.20–1.50 0.999 53.87 0.67 0.49 1.37 0.197 1.56
imp-B 0.27–1.50 0.998 33.44 0.65 0.38 1.74 0.10 0.97
Table 5 LOD and LOQ results for ACTR and its RS.
Compound LOD LOQ
Concentration (mg) RSD (%) of injection (n¼6) Concentration (mg) RSD (%) of injection (n¼6)
ACTR 0.12 11.4 0.35 6.9
Tretintoin 0.07 9.8 0.2 4.3
imp-A 0.07 10.9 0.2 5.3
imp-B 0.1 16.8 0.27 7.7
Table 6 Intra-day and intermediate precision of ACTR and its RS (RSD (%) of n¼6 injections).
Compound Intraday precision Intermediate precision
System precision Method precision Different day
ACTR 0.3 1.0 0.9
Tretintoin 0.8 1.7 0.7
imp-A 0.9 1.2 1.0
imp-B 0.4 1.9 1.7
Total impurity 0.8 1.9 1.4
Table 7 Accuracy results of ACTR and its related substances in the term of RSD(%) of mean recovery.
Added (%) ACTR Tretintoin imp-A imp-B
MR (%) RSD (%) MR (%) RSD (%) MR (%) RSD (%) MR (%) RSD (%)
50 99.8 1.9 98.2 1.5 99.6 2.2 97.5 3.1
100 101.2 2.0 99.5 2.1 102.8 2.4 100.2 1.9
150 100.9 1.4 100.5 2.4 98.4 1.5 100.9 2.1
300 101.7 1.9 98.9 1.6 99.1 2.1 99.0 1.3
MR; mean recovery, n¼3.
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following equation:
FR ¼ Simpurity=SACTR
where Simpurity is the slope of the regression line for a given
impurity and SACTR is the slope of the regression line for ACTR.
Concentrations of ACTR and impurity were corrected. Statistical
treatment of the linearity data of ACTR shows a linear response
from lowest to highest level. In addition, the analysis of residuals
shows values randomly scattered around zero, which ﬁts well
within the linear model. The origin of the linearity curve was
within the lower and the upper limit of 95% and gives a high
degree of conﬁdence to the value obtained for intercept.3.6. LOD and LOQ
LOD and LOQ, as measures of method sensitivity, were determined for
degradation products and impurity was calculated by means of signal-
to-noise ratio. The LOD and LOQ for ACTR and its RS are shown in
Table 5. From the results it can be concluded that the proposed method
can quantify small amounts of impurities in ACTR samples.3.7. Precision and repeatability
The results obtained for repeatability studies and for intermediate
precision are presented in Table 6. Values of RSD (%) for system
Table 8 Stability of ACTR and its related substances in analytical solution (1-day study).
Compound Initial area 12 h 18 h 24 h
Area Difference (%) Area Difference (%) Area Difference (%)
ACTR 36.15969 37.01846 2.4 37.59764 4.0 36.86213 1.9
Tretintoin 13.71313 14.14156 3.1 13.67648 0.3 13.71130 0.0
imp-A 89.97086 89.69975 0.3 91.34973 1.5 92.72081 3.1
imp-B 9.40208 9.34010 0.7 9.03424 3.9 9.74495 3.6
Total impurity 172.59161 172.62739 0.0 172.37648 0.1 176.39990 2.2
Table 9 Effect of various speciﬁc changes on the system suitability parameters.
System suitability conditions Ratio between the duplicate injection RSD (%) for ACTR standard replicate injections
Change in ﬂow rate (mL) 0.8 1.01 1.06
1.0 0.97 1.06
1.2 0.99 1.54
Change in column temperature (1C) 25 1.02 1.78
30 0.97 1.06
35 1.00 0.62
Change in IPA (%) 27.7 0.99 1.63
29.7 0.97 1.06
31.7 1.04 1.61
Degradation behavior of acitretin 445precision of ACTR and total impurities were 0.3 and 0.8,
respectively. Method precision has a RSD (%) below 1.9 for
repeatability and 1.4 for intermediate precision, which comply
with the acceptance criteria.
3.8. Accuracy
The results are expressed as percent recoveries of the particular
components in the samples. Table 7 shows the overall percent
recoveries of ACTR and its six RS at 50%, 100%, 200% and
300% of the test concentration. The method shows consistent
recoveries for ACTR (99.8%–101.2%). The related compounds
showed overall percent recoveries ranging from 97.9% to 102.8%
with RSD (%) ranging from 1.2 to 3.1.
3.9. Stability in analytical solution
The area change (%) in peaks of ACTR and all impurities was less
than 2.0% and 5.0%, respectively. From the data shown in
Table 8, it was concluded that standard and sample solutions
may be used up to 24 h after preparation.
3.10. Robustness
Method robustness was checked after deliberate alterations of
mobile phase composition, ﬂow, pH and temperature which shows
that the changes of the operational parameters do not lead to
signiﬁcant changes in the performance of the chromatographic
system; results are displayed in Table 9. The tailing factor for
ACTR and the RS always ranged from 1 to 1.5 and the
components were well separated. The recoveries (%) of ACTR
and RS were good and did not show a signiﬁcant change when the
critical parameters were modiﬁed. Considering the results of
modiﬁcations in the system suitability parameters and thespeciﬁcity of the method, we conclude that the method conditions
are robust.4. Conclusions
We developed an HPLC method for estimation of related substances
for acitretin, analyzed in bulk drug and ACTR capsule as per ICH
guidelines. The method was found to be speciﬁc for the estimation
of known and unknown impurities and degradation products. The
method can also be used to determine acitretin stability. The assay
utilized a previously unreported set of conditions, including simple
mobile phases, to effect separation without using an ion-pair
reagent. LOD and LOQ, established by this method, are less than
the previously reported methods. The method is found to be linear
in the speciﬁed range, precise and robust. Accuracy of the method is
also established for the formulation. Hence, the proposed method
may be used for routine stability sample analysis.
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